10.1016/j.jep.2022.115333 78 LiangZ.PiD.ZhenJ.YanH.ZhengC.Liang ChenJ.et al (2024)
Orforglipron significantly reduced HbA1c to 2.1% in a phase II clinical trial assessing its use in T2DM, while dulaglutide achieved 1.1% and a placebo achieved 0.43% [106]
What the FDA will review (and when) According to the FDA Law Blog breakdown, the FDA has scheduled the Pharmacy Compounding Advisory Committee (PCAC) to review peptides for possible inclusion on the Section 503A bulks list on two timelines: PCAC meeting: July 2324, 2026 July 23: BPC-157, KPV, TB-500, MOTs-C (FDA Law Blog) July 24: Emideltide (DSIP), Semax, Epithalon (FDA Law Blog) Second PCAC meeting: before the end of February 2027 GHK-Cu, Melanotan II, Cathelicidin (LL-37), Dihexa acetate, PEG-MGF (FDA Law Blog) Well update this post as the FDA releases briefing packets, conflict-of-interest disclosures, and voting questions closer to the meeting
Green Papaya: How Do They Really Whiten the Skin
